Amplia Therapeutics Says US Council Adopts Name for Cancer Drug Candidate; Shares Fall 3%

MT Newswires Live2025-09-02

Amplia Therapeutics (ASX:ATX) said the United States Adopted Names Council adopted narmafotinib as the generic name for its inhibitor targeting focal adhesion kinase, a non-receptor protein tyrosine kinase being developed for pancreatic cancer, according to a Tuesday filing with the Australian bourse.

A clinical trial of narmafotinib in combination with the folfirinox chemotherapy regimen as a potential treatment for pancreatic cancer will be conducted in the US and Australia, per the filing. The study will assess the treatment candidate's safety, tolerability, and efficacy, among others.

Shares of the company fell past 3% in recent Tuesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2564340827?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 11:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564340827","market":"nz","top_or_hot":-1,"title":"Amplia Therapeutics Says US Council Adopts Name for Cancer Drug Candidate; Shares Fall 3%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) said the United States Adopted Names Council adopted narmafotinib as the generic name for its inhibitor targeting focal adhesion kinase, a non-receptor protein tyrosine kinase being developed for pancreatic cancer, according to a Tuesday filing with the Australian bourse.</p><p>A clinical trial of narmafotinib in combination with the folfirinox chemotherapy regimen as a potential treatment for pancreatic cancer will be conducted in the US and Australia, per the filing. The study will assess the treatment candidate's safety, tolerability, and efficacy, among others.</p><p>Shares of the company fell past 3% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amplia Therapeutics Says US Council Adopts Name for Cancer Drug Candidate; Shares Fall 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmplia Therapeutics Says US Council Adopts Name for Cancer Drug Candidate; Shares Fall 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-02 11:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) said the United States Adopted Names Council adopted narmafotinib as the generic name for its inhibitor targeting focal adhesion kinase, a non-receptor protein tyrosine kinase being developed for pancreatic cancer, according to a Tuesday filing with the Australian bourse.</p><p>A clinical trial of narmafotinib in combination with the folfirinox chemotherapy regimen as a potential treatment for pancreatic cancer will be conducted in the US and Australia, per the filing. The study will assess the treatment candidate's safety, tolerability, and efficacy, among others.</p><p>Shares of the company fell past 3% in recent Tuesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XJO.AU","symbol_name":"标普/澳交所 200指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2564340827","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564340827","pubTimestamp":1756784464,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amplia Therapeutics  said the United States Adopted Names Council adopted narmafotinib as the generic name for its inhibitor targeting focal adhesion kinase, a non-receptor protein tyrosine kinase being developed for pancreatic cancer, according to a Tuesday filing with the Australian bourse.A clinical trial of narmafotinib in combination with the folfirinox chemotherapy regimen as a potential treatment for pancreatic cancer will be conducted in the US and Australia, per the filing. The study will assess the treatment candidate's safety, tolerability, and efficacy, among others.Shares of the company fell past 3% in recent Tuesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XJO.AU":"标普/澳交所 200指数","BK4539":"次新股","XKO.AU":"标普/澳交所 300指数","ATX.AU":"AMPLIA THERAPEUTICS LTD","BK7067":"生物科技","XAO.AU":"标普/澳交所 普通股指数","BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药"},"translate_title":"Amplia Therapeutics表示美国委员会采用癌症候选药物名称；股价下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XAO.AU":0.85,"XJO.AU":0.85,"XKO.AU":0.85,"ATX.AU":0.9,"LENZ":1},"content_text":"Amplia Therapeutics (ASX:ATX) said the United States Adopted Names Council adopted narmafotinib as the generic name for its inhibitor targeting focal adhesion kinase, a non-receptor protein tyrosine kinase being developed for pancreatic cancer, according to a Tuesday filing with the Australian bourse.A clinical trial of narmafotinib in combination with the folfirinox chemotherapy regimen as a potential treatment for pancreatic cancer will be conducted in the US and Australia, per the filing. The study will assess the treatment candidate's safety, tolerability, and efficacy, among others.Shares of the company fell past 3% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2564340827","isCrawlerRequest":true}